All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2019-12-17T11:29:40.000Z

What is the role of immune checkpoint directed therapy in the treatment of AML?

By Emily Smith, Amer Zeidan
Featured
Amer Zeidan
Dec 17, 2019
Share:

Bookmark this article

During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the AML Global Portal were delighted to speak to Amer Zeidan, Yale School of Medicine, New Haven, US. We asked: What is the role of immune checkpoint directed therapy in the treatment of acute myeloid leukemia (AML)?

Amer Zeidan discusses a large randomized trial in patients with AML and myelodysplastic syndromes (MDS) investigating immune checkpoint blockade. In total, 213 patients were randomized to receive azacitidine (AZA) or AZA with an anti-PDL1 inhibitor durvalumab . Whilst the final results did not show a difference in overall response rate (ORR), it was noted that the study has provided invaluable information about how immune checkpoint blockade plays a role in AML.

What is the role of immune checkpoint directed therapy in the treatment of AML?

More about...
ASH 2019AzacitidineChromosomal aberrationsDurvalumabMyelodysplasia-related

Related articles

Add bookmark

Naval Daver | EHA 2018 | Immune-based therapy in AML

Naval Daver: MD Anderson Cancer Center, Houston, US Interview topic: Immune-based therapy in AML

Jun 19, 2018
Add bookmark

Naval Daver | EHA 2018 | Immune-based therapy in AML

Naval Daver: MD Anderson Cancer Center, Houston, US Interview topic: Immune-based therapy in AML

Jun 19, 2018
Add bookmark

Molecular diagnosis and treatment for AML – Educational session at the 22nd congress of the EHA

At the 22nd Congress of the European Hematology Association (EHA), Madrid, Spain, the AGP were delighted to attend an educational session on AML.

Jul 6, 2017
Add bookmark

Molecular diagnosis and treatment for AML – Educational session at the 22nd congress of the EHA

At the 22nd Congress of the European Hematology Association (EHA), Madrid, Spain, the AGP were delighted...

Jul 6, 2017

Newsletter

Subscribe to get the best content related to AML delivered to your inbox